BLTE
HEALTHCAREBelite Bio Inc
$156.21+1.83 (+1.19%)PRE
Live · NASDAQ · May 8, Close
AI Insight
What's Moving BLTE Today?
No stock-specific AI insight has been generated for BLTE yet. Check back soon — insights are generated from recent news analysis.
52-Week Range
$56.10$200.00
$156.21
Fundamentals
Market Cap$6.2B
P/E Ratio—
EPS$-2.30
Dividend Yield—
Dividend / Share—
ROE-0.2%
Profit Margin—
Debt / Equity—
Trading
Volume174K
Avg Volume (10D)—
Shares Outstanding40.0M
BLTE News
20 articles- Belite Bio (BLTE) Valuation Check As Tinlarebant Advances With Rolling FDA NDA SubmissionYahoo Finance·May 3, 2026
- Belite Bio (BLTE) Initiates Rolling NDA Submission to FDA for Tinlarebant in STGD1Yahoo Finance·May 1, 2026
- Deutsche Bank ADR Virtual Investor Conference: Presentations Now Available for Online ViewingYahoo Finance·Apr 29, 2026
- Belite Bio Shares Tinlarebant Phase III Stargardt Data, FDA Rolling Submission at DB ConferenceMarketbeat·Apr 28, 2026
- Belite Bio Announces Oral Presentation at the Retinal Therapeutics Innovation SummitYahoo Finance·Apr 27, 2026
- How Belite Bio’s (BLTE) Rolling FDA NDA For Tinlarebant Has Changed Its Investment StoryYahoo Finance·Apr 24, 2026
- International companies to host live webcasts at Deutsche Bank’s Depositary Receipts Virtual Investor Conference on April 28, 2026Yahoo Finance·Apr 23, 2026
- Belite Bio to Participate in Four Upcoming Investor ConferencesYahoo Finance·Apr 23, 2026
- Belite Bio to Present at the Deutsche Bank American Depositary Receipt Virtual Investor Conference on April 28thYahoo Finance·Apr 22, 2026
- Belite Bio Initiates Rolling Submission of New Drug Application to the U.S. Food and Drug Administration for Tinlarebant for the Treatment of Stargardt DiseaseGlobeNewswire Inc.·Apr 21, 2026
- When Can We Expect A Profit From Belite Bio, Inc (NASDAQ:BLTE)?Yahoo Finance·Apr 13, 2026
- Belite Bio Announces Availability of Annual Report on Form 20-F Through Company WebsiteYahoo Finance·Mar 31, 2026
- Belite Bio Details Phase 3 DRAGON Win as Tinlarebant Cuts Stargardt Lesion Growth 36% at ConferenceMarketbeat·Mar 10, 2026
- Belite Bio price target raised to $266 from $200 at Cantor FitzgeraldYahoo Finance·Mar 4, 2026
- Belite Bio Advances Tinlarebant Toward FDA Review After DRAGON SuccessYahoo Finance·Mar 3, 2026
- Belite Bio (BLTE) Q4 2025 Earnings Call TranscriptMotley Fool·Mar 3, 2026
- Belite Bio Inc (BLTE) Q4 2025 Earnings Call Highlights: Strategic Advances and Financial ChallengesYahoo Finance·Mar 3, 2026
- Belite Bio Q4 Earnings Call HighlightsMarketbeat·Mar 2, 2026
- Belite Bio to Participate in the Leerink Global Healthcare ConferenceYahoo Finance·Mar 2, 2026
- Belite Bio Reports Preliminary, Unaudited Fourth Quarter and Full Year 2025 Financial Results and Provides a Corporate UpdateYahoo Finance·Mar 2, 2026
All 20 articles loaded
Price Data
Open$0.00
Previous Close$154.38
Day High$0.00
Day Low$0.00
52 Week High$200.00
52 Week Low$56.10
52-Week Range
$56.10$200.00
$156.21
Fundamentals
Market Cap$6.2B
P/E Ratio—
EPS$-2.30
Dividend Yield—
Dividend / Share—
ROE-0.2%
Profit Margin—
Debt / Equity—
Trading
Volume174K
Avg Volume (10D)—
Shares Outstanding40.0M
About Belite Bio Inc
Belite Bio, Inc, a clinical-stage biopharmaceutical drug development company, is engaged in the research and development of novel therapies targeting age-related atrophic macular degeneration and autosomal recessive stargardt diseases. The company is headquartered in San Diego, California.
HEALTHCAREBIOTECHNOLOGY
Company Details
Security TypeStock
ExchangeNASDAQ
CurrencyUSD
Round Lot—
SICBIOTECHNOLOGY
CIK—
Composite FIGI—
Share Class FIGI—